Oncimmune is a pioneer and leader in the use of autoantibodies as one of the earliest, measurable signals of disease.
ImmunoINSIGHTS is Oncimmune’s autoantibody profiling service to the life science industry in the fields of immuno-oncology, autoimmune disease and infectious diseases. This is underpinned by our proprietary, immunogenic protein library of almost 9,000 antigens, one of the largest in the world, covering more than 95% of known human antigens. Our platform enables high-throughput profiling of autoantibodies in patients receiving or about to receive treatment.
Oncimmune’s core biomarker technology and expertise in the immune system enables life-science organisations to understand the immune response to therapy, leading to more effective, and safer treatments for patients.
The ImmunoINSIGHTS service can be utilised to:
- Stratify patients into clinically relevant sub-groups
- Predict response to treatment and immune-related adverse events (irAEs)1
- Characterise the disease state and define the disease
- Understand the immune response to disease (e.g. COVID-19)
- Identify novel target molecules
- Detect treatment-specific immune excitation (e.g. Heating of cold tumours)2,3
- Predict off-target effects and non-specific binding of therapeutics
- Hassel, JC. Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma. Oral Presentation, ASCO Annual Conference (2020)
- Schulz-Knappe P, Budde P, Zucht H-D, et al. THU0042 Cancer immunotherapy array: a novel screening tool for immune system profiling in cancer immunotherapy bridging autoimmunity and cancer. Ann Rheum Dis 2018;77:247–247. doi:10.1136/annrheumdis-2018-eular.6712
- Budde P, Marte JL, Zucht H-D et al. THU0043 Autoantibody profiling in prostvac and ipilimumab treated prostate cancer patients reveals potential biomarkers of immune-related adverse events. Annals of the Rheumatic Diseases 2018; 77(Suppl 2):247–247.
Oncimmune is leading the way in understanding how the immune system reacts to disease by generating invaluable patient-specific insights from the measurement and characterisation of the autoantibody response.
Mike Fisher, Vice President, Head of Business Development